Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Nörder, Miriam ^a   Becker, Pablo D ^a   Drexler, Ingo ^b   Link, Claudia ^a   Erfle, Volker ^b   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MODIFIED VACCINIA VIRUS ANKARA VACCINE; OVALBUMIN; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EMBRYO; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ANIMAL; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; C57BL MOUSE; CD8+ T LYMPHOCYTE; CHEMISTRY; IMMUNIZATION; IMMUNOLOGY; SAFETY; SOLUBILITY; VACCINIA VIRUS;

MURINAE; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OVALBUMIN; SAFETY; SOLUBILITY; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL VACCINES;

EID: 77955329674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011400     Document Type: Article

References (49)

1. Drexler I, Heller K, Wahren B, Erfle V, Sutter G (1998) Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79(Pt 2): 347-352.
2. Carroll MW, Moss B (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
3. Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72(Pt 5): 1031-1038.
4. Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
5. Blanchard TJ, Alcami A, Andrea P, Smith GL (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79(Pt 5): 1159-1167.
6. Mayr A, Stickl H, Muller HK, Danner K, Singer H (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 167: 375-390.
7. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, et al. (1974) [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 99: 2386-2392.
8. Slifka MK (2005) The Future of Smallpox Vaccination: is MVA the key? Med Immunol 4: 2
9. Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, et al. (2003) Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J Infect Dis 188: 1239-1244.
10. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, et al. (2006) Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24: 3026-3034.
11. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, et al. (2006) Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6.year old children in a malaria endemic area. Vaccine 24: 4709-4715.
12. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, et al. (2006) Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80: 4705-4716.
13. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, et al. (2007) Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25: 3277-3283.
14. Burgers WA, Shephard E, Monroe JE, Greenhalgh T, Binder A, et al. (2008) Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 24: 195-206.
15. Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, et al. (2005) A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 54: 453-467.
16. Rock KL, Hearn A, Chen CJ, Shi Y (2005) Natural endogenous adjuvants. Springer Semin Immunopathol 26: 231-246.
17. Brimnes MK, Bonifaz L, Steinman RM, Moran TM (2003) Influenza virusinduced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med 198: 133-144.
18. Rocha CD, Caetano BC, Machado AV, Bruna-Romero O (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7: 83-94.
19. Souza AP, Haut L, Reyes-Sandoval A, Pinto AR (2005) Recombinant viruses as vaccines against viral diseases. Braz J Med Biol Res 38: 509-522.
20. Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, et al. (2002) Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76: 127-135.
21. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, et al. (2008) Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 118: 1776-1784.
22. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
23. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, et al. (1999) Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 163: 6762-6768.
24. Shortman K (2000) Burnet oration: dendritic cells: multiple subtypes, multiple origins, multiple functions. Immunol Cell Biol 78: 161-165.
25. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
26. Liu L, Chavan R, Feinberg MB (2008) Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 9: 15
27. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I (2007) Crosspriming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81: 11925-11936.
28. Behboudi S, Moore A, Gilbert SC, Nicoll CL, Hill AV (2004) Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine 22: 4326-4331.
29. Drillien R, Spehner D, Hanau D (2004) Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol 85: 2167-2175.
30. Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, et al. (2006) Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350: 276-288.
31. Hutchings CL, Gilbert SC, Hill AV, Moore AC (2005) Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175: 599-606.
32. Hutchings CL, Birkett AJ, Moore AC, Hill AV (2007) Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 75: 5819-5826.
33. Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, et al. (2007) Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204: 2187-2198.
34. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 18: 265-270.
35. Manz RA, Radbruch A (2002) Plasma cells for a lifetime? Eur J Immunol 32: 923-927.
36. Manz RA, Thiel A, Radbruch A (1997) Lifetime of plasma cells in the bone marrow. Nature 388: 133-134.
37. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, et al. (2003) Tcell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 9: 526-534.
38. Chahroudi A, Garber DA, Reeves P, Liu L, Kalman D, et al. (2006) Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 80: 8469-8481.
39. Humrich JY, Thumann P, Greiner S, Humrich JH, Averbeck M, et al. (2007) Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells. Eur J Immunol 37: 954-965.
40. Ramirez JC, Gherardi MM, Esteban M (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of Band T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74: 923-933.
41. Clarke SR, Barnden M, Kurts C, Carbone FR, Miller JF, et al. (2000) Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 78: 110-117.
42. Kelly JM, Sterry SJ, Cose S, Turner SJ, Fecondo J, et al. (1993) Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant. Eur J Immunol 23: 3318-3326.
43. Robertson JM, Jensen PE, Evavold BD (2000) DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339.epitope. J Immunol 164: 4706-4712.
44. Staib C, Lowel M, Erfle V, Sutter G (2003) Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 34: 694-696., 698-700
45. Lipford GB, Hoffman M, Wagner H, Heeg K (1993) Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150: 1212-1222.
46. Catipovic B, Dal Porto J, Mage M, Johansen TE, Schneck JP (1992) Major histocompatibility complex conformational epitopes are peptide specific. J Exp Med 176: 1611-1618.
47. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.
48. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.
49. Becker PD, Norder M, Guzman CA, Grinstein S (2007) Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice. Clin Vaccine Immunol 14: 538-543.